ERAS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
ERAS 近期報酬表現
-2.12%
Erasca inc
2.35%
同產業平均
-0.21%
S&P500
與 ERAS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
FTRE | Fortrea holdings inc | - | 2 分 | 1 分 | 3 分 | 1 分 | |
DTIL | Precision biosciences inc | 4 分 | 3 分 | 4 分 | 1 分 | 1 分 | |
BEAM | Beam therapeutics inc | 3 分 | 3 分 | 2 分 | 3 分 | 1 分 | |
AGIO | Agios pharmaceuticals inc | 3 分 | 5 分 | 3 分 | 3 分 | 1 分 | |
TSBX | Turnstone biologics corp | - | 2 分 | 2 分 | 1 分 | 1 分 |
- FTRE Fortrea holdings inc價值 -趨勢 2 分波段 1 分籌碼 3 分股利 1 分查看更多
ERAS 公司資訊
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.